ArticleStem cell research & therapy2017
High quality clinical grade human embryonic stem cell lines derived from fresh discarded embryos.
Article in Stem cell research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 51 citations in OpenAlex.
- A simple and standardized method supports efficient derivation of clinical-grade human embryonic stem cells under feeder- and xeno-free conditions.Stem cell research & therapy · 2025Article
- Extracellular domain shedding of NOTCH3 during endocytosis associated with heterogeneity between different CADASIL mutant activation mechanisms.Cell communication and signaling : CCS · 2025Article
- Recent Advancements in the Generation and Application of Therapeutic Cell Populations for Lung Epithelial Repair.Journal of tissue engineering and regenerative medicine · 2025Review
- Human Brain In Vitro Model for Pathogen Infection-Related Neurodegeneration Study.International journal of molecular sciences · 2024Review
- A secreted proteomic footprint for stem cell pluripotency.PloS one · 2024Article
- Article
- Challenges Facing the Translation of Embryonic Stem Cell Therapy for the Treatment of Cartilage Lesions.Stem cells translational medicine · 2022Review
- Article
- The Manufacture of Xeno- and Feeder-Free Clinical-Grade Human Embryonic Stem Cell Lines: First Step for Cell Therapy.International journal of molecular sciences · 2022Article
- SIRT1 activity orchestrates ECM expression during hESC-chondrogenic differentiation.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- Development of human cartilage circadian rhythm in a stem cell-chondrogenesis model.Theranostics · 2022Article
- Semi-3D cultures using Laminin 221 as a coating material for human induced pluripotent stem cells.Regenerative biomaterials · 2022Article
- Developing standards to support the clinical translation of stem cells.Stem cells translational medicine · 2021Review
- Article
- Off-the-Shelf, Immune-Compatible Human Embryonic Stem Cells Generated Via CRISPR-Mediated Genome Editing.Stem cell reviews and reports · 2021Article
- The miR-199a/214 Cluster Controls Nephrogenesis and Vascularization in a Human Embryonic Stem Cell Model.Stem cell reports · 2021Article
- Optogenetic Control of the BMP Signaling Pathway.ACS synthetic biology · 2020Article
- Emulating Human Tissues and Organs: A Bioprinting Perspective Toward Personalized Medicine.Chemical reviews · 2020Review
- Clinical-Grade Human Pluripotent Stem Cells for Cell Therapy: Characterization Strategy.International journal of molecular sciences · 2020Review
- Generation of Human-Induced Pluripotent Stem Cells From Anterior Cruciate Ligament.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 2 countries.
Funding
Abstract
backgroundHuman embryonic stem cells (hESCs) hold tremendous promise for cell replacement therapies for a range of degenerative diseases. In order to provide cost-effective treatments affordable by public health systems, HLA-matched allogeneic tissue banks of the highest quality clinical-grade hESCs will be required. However only a small number of existing hESC lines are suitable for clinical use; they are limited by moral and ethical concerns and none of them apply Good Manufacturing Practice (GMP) standards to the earliest and critical stages of gamete and embryo procurement. We thus aimed to derive new clinical grade hESC lines of highest quality from fresh surplus GMP grade human embryos.
methodsA comprehensive screen was performed for suitable combinations of culture media with supporting feeder cells or feeder-free matrix, at different stages, to support expansion of the inner cell mass and to establish new hESC lines.
resultsWe developed a novel two-step and sequential media system of clinical-grade hESC derivation and successfully generated seven new hESC lines of widely varying HLA type, carefully screened for genetic health, from human embryos donated under the highest ethical and moral standards under an integrated GMP system which extends from hESC banking all the way back to gamete and embryo procurement.
conclusionsThe present study, for the first time, reports the successful derivation of highest-quality clinical-grade hESC lines from fresh poor-quality surplus human embryos generated in a GMP-grade IVF laboratory. The availability of hESC lines of this status represents an important step towards more widespread application of regenerative medicine therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.